BioVector? RIL-175 小鼠肝細(xì)胞癌細(xì)胞系 / Mouse Hepatocellular Carcinoma Cell Line 數(shù)據(jù)說明書

產(chǎn)品名稱: BioVector? RIL175 細(xì)胞
同義詞: BioVector? RIL-175
中文名稱: BioVector? RIL175 小鼠肝細(xì)胞癌細(xì)胞系
英文名稱: BioVector? RIL175 Mouse Hepatocellular Carcinoma Cell Line
產(chǎn)品類別: 腫瘤細(xì)胞系；肝癌研究模型
物種來源: 小鼠 (Mus musculus)，C57BL/6 品系
組織來源: 胚胎肝組織
細(xì)胞類型: 肝細(xì)胞癌細(xì)胞
疾病: 肝細(xì)胞癌 (Hepatocellular carcinoma, HCC)
細(xì)胞來源: 源自 p53 基因敲除小鼠胚胎肝細(xì)胞，通過轉(zhuǎn)導(dǎo)攜帶 p.Gly12Val 突變的 HRAS 癌基因轉(zhuǎn)化建立
基因特征:

1. Trp53 敲除: 采用基因敲除小鼠技術(shù)構(gòu)建，Trp53 基因功能缺失

2. HRAS 突變: 穩(wěn)定整合 HRAS 基因并表達(dá) p.Gly12Val 突變型 HRAS 蛋白

3. 致瘤性: 在 C57BL/6 同系小鼠中具有高度致瘤性，可用于建立原位肝癌模型
   形態(tài)特性: 上皮細(xì)胞樣
   生長特性: 貼壁生長
   特性特征:

4. 免疫活性模型: 來源于 C57BL/6 小鼠，可在免疫健全的同系小鼠中建立腫瘤模型，適用于腫瘤免疫學(xué)研究

5. 原位成瘤: 通過原位注射可建立穩(wěn)定的肝細(xì)胞癌模型，模擬人肝癌的腫瘤微環(huán)境

6. 免疫治療研究: 廣泛用于抗 PD-1 抗體、腺苷 A2a 受體抑制劑等免疫檢查點抑制劑的療效評估

7. 耐藥模型: 衍生出索拉非尼耐藥亞系 BioVector? RIL175-R，用于肝癌耐藥機制研究

8. 基因編輯: 已建立 TRPML1 基因敲除亞系，用于研究溶酶體功能與線粒體代謝的關(guān)系

9. 聯(lián)合治療: 常用于評估聯(lián)合治療策略，如抗 PD-1 與抗 CXCR4 聯(lián)合、A2aR 抑制劑與免疫治療聯(lián)合等
   研究應(yīng)用:

10. 肝細(xì)胞癌發(fā)病機制研究

11. 腫瘤免疫治療療效評估

12. 免疫檢查點抑制劑聯(lián)合治療策略開發(fā)

13. 肝癌耐藥機制研究

14. 腫瘤微環(huán)境與免疫細(xì)胞相互作用研究

15. 線粒體功能與腫瘤代謝研究
    培養(yǎng)基: BioVector? RIL175 細(xì)胞專用完全培養(yǎng)基（推薦基礎(chǔ)成分：DMEM 高糖培養(yǎng)基，添加 20% 胎牛血清、1 mM 丙酮酸鈉和 1% 青霉素-鏈霉素）
    培養(yǎng)條件: 氣相：95% 空氣，5% 二氧化碳；溫度：37°C
    傳代方法: 當(dāng)細(xì)胞融合度達(dá)到 80-90% 時，推薦使用 BioVector? 專用傳代試劑（如 0.25% 胰蛋白酶-EDTA）進(jìn)行消化，按 1:3 至 1:6 比例進(jìn)行傳代，每周傳代 2-3 次
    凍存液: BioVector? 細(xì)胞凍存液（推薦配方：90% 胎牛血清 + 10% DMSO）
    質(zhì)量控制: 支原體檢測：陰性；無菌檢測：陰性；STR 分型：已驗證；致瘤性驗證：陽性
    儲存與運輸: 液氮或干冰運輸與保存
    生物安全等級: 1（需在二級生物安全柜內(nèi)操作）
    相關(guān)細(xì)胞系: BioVector? RIL175-R（索拉非尼耐藥亞系）；BioVector? RIL175 TRPML1 KO（TRPML1 基因敲除亞系）
    僅供科研使用

English:
BioVector? RIL175 Mouse Hepatocellular Carcinoma Cell Line Datasheet

Product Name: BioVector? RIL175 Cells
Synonyms: BioVector? RIL-175
Chinese Name: BioVector? RIL175 小鼠肝細(xì)胞癌細(xì)胞系
English Name: BioVector? RIL175 Mouse Hepatocellular Carcinoma Cell Line
Product Category: Cancer Cell Line; Liver Cancer Research Model
Species of Origin: Mouse (Mus musculus), C57BL/6 strain
Tissue of Origin: Embryonic liver tissue
Cell Type: Hepatocellular carcinoma cells
Disease: Hepatocellular carcinoma (HCC)
Derivation: Derived from p53 knockout mouse embryonic hepatocytes, transformed by transduction with HRAS oncogene carrying p.Gly12Val mutation
Genetic Features:

1. Trp53 Knockout: Trp53 gene knockout via KO mouse technology, resulting in loss of function

2. HRAS Mutation: Stably integrated HRAS gene expressing p.Gly12Val mutant HRAS protein

3. Tumorigenicity: Highly tumorigenic in syngeneic C57BL/6 mice, suitable for establishing orthotopic liver cancer models
   Morphology: Epithelial-like
   Growth Characteristics: Adherent
   Characteristics:

4. Immunocompetent Model: Derived from C57BL/6 mice, enables tumor model establishment in immunocompetent syngeneic mice, suitable for tumor immunology research

5. Orthotopic Tumor Formation: Stable hepatocellular carcinoma model established via orthotopic injection, recapitulating the tumor microenvironment of human HCC

6. Immunotherapy Research: Widely used for efficacy evaluation of immune checkpoint inhibitors such as anti-PD-1 antibodies and adenosine A2a receptor inhibitors

7. Drug Resistance Model: Sorafenib-resistant subline BioVector? RIL175-R available for HCC resistance mechanism studies

8. Gene Editing: TRPML1 knockout subline established for investigating lysosomal function and mitochondrial metabolism

9. Combination Therapy: Commonly used for evaluating combination therapy strategies, including anti-PD-1 with anti-CXCR4, A2aR inhibitors with immunotherapy, etc.
   Research Applications:

10. Hepatocellular carcinoma pathogenesis studies

11. Tumor immunotherapy efficacy evaluation

12. Immune checkpoint inhibitor combination therapy strategy development

13. HCC drug resistance mechanism studies

14. Tumor microenvironment and immune cell interaction studies

15. Mitochondrial function and tumor metabolism studies
    Culture Medium: BioVector? Complete Medium for RIL175 Cells (Recommended composition: DMEM high glucose medium supplemented with 20% fetal bovine serum, 1 mM sodium pyruvate, and 1% penicillin-streptomycin)
    Culture Conditions: Atmosphere: 95% air, 5% CO?; Temperature: 37°C
    Subculturing Method: When cells reach 80-90% confluence, recommended to use BioVector? Subculture Reagent (e.g., 0.25% Trypsin-EDTA). Subculture at a split ratio of 1:3 to 1:6, 2-3 times per week
    Freeze Medium: BioVector? Cell Freeze Medium (Recommended composition: 90% FBS + 10% DMSO)
    Quality Control: Mycoplasma: Negative; Sterility: Negative; STR Profiling: Authenticated; Tumorigenicity Validation: Positive
    Storage and Shipment: Stored and shipped in liquid nitrogen or on dry ice
    Biosafety Level: 1 (Operate in a Class II biological safety cabinet)
    Related Cell Lines: BioVector? RIL175-R (Sorafenib-resistant subline); BioVector? RIL175 TRPML1 KO (TRPML1 knockout subline)
    For Research Use Only

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com